将新型药物纳入急性髓系白血病的治疗中。
Incorporating newer agents in the treatment of acute myeloid leukemia.
作者信息
Raj Renju V, Abedin Sameem M, Atallah Ehab
机构信息
Divison of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States.
Divison of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States.
出版信息
Leuk Res. 2018 Nov;74:113-120. doi: 10.1016/j.leukres.2018.10.008. Epub 2018 Oct 19.
Prognosis for patients with AML remains dismal. Despite multiple clinical trials across several decades, little improvement for the therapy of non-APL AML was noted. However, over the last couple of years, several new therapies have demonstrated efficacy in the therapy of patients with AML. Several of those have been approved by the FDA for AML therapy. These include CPX-351, midostaurin, gemtuzumab ozogamicin, enasidenib and ivosidenib. Our goal in this review is to summarize currently available data on these new therapies and discuss the rapidly evolving treatment landscape of AML.
急性髓系白血病（AML）患者的预后仍然不容乐观。尽管几十年来进行了多项临床试验，但非急性早幼粒细胞白血病（APL）AML的治疗进展甚微。然而，在过去几年中，几种新疗法已在AML患者治疗中显示出疗效。其中几种已获美国食品药品监督管理局（FDA）批准用于AML治疗。这些疗法包括CPX-351、米哚妥林、吉妥珠单抗奥唑米星、恩杂鲁胺和艾伏尼布。本综述的目的是总结这些新疗法的现有数据，并讨论AML迅速演变的治疗格局。
Zotero 插件